Medifast Inc. (MED) Insider Trading
Insiders bought $1.67M and sold $226k on the open market.
All of the selling was scheduled in advance under 10b5-1 plans.
Get an email when MED's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 28 – 29 | Daniel R Chard Director | Sold10b5-1 plan 2 parts | 19,089 | $11.86 average | $226k | 5.4% | Form 4 |
| Aug 26 | Parsa Kiai Director | Bought 2 parts | 43,150 | $12.26 average | $529k | New | Form 4 |
| Aug 24 | Parsa Kiai Director | Bought 2 parts | 4,329 | $12.00 average | $52k | 29% | Form 4 |
| Aug 19 – 20 | Parsa Kiai Director | Bought 4 parts | 72,487 | $11.62 average | $843k | New | Form 4 |
| May 8 – 11 | Scott Schlackman Director | Bought 2 parts | 5,000 | $12.59 average | $63k | 20% | Form 4 |
| Mar 20 | Daniel R Chard Chairman & CEO | Bought | 17,678 | $10.11 | $179k | 5.2% | Form 4 |
| Jun 13, 2025 | Daniel R Chard Chairman & CEO | Bought | 381 | $13.13 | $5k | 0.1% | Form 4 |
- Sep 28 – 2910b5-1 planDaniel R ChardDirector · sold 19,089 at avg $11.86$226k5.4% of stake
- Aug 26Parsa KiaiDirector · bought 43,150 at avg $12.26$529kNew position
- Aug 24Parsa KiaiDirector · bought 4,329 at avg $12.00$52k29% of stake
- Aug 19 – 20Parsa KiaiDirector · bought 72,487 at avg $11.62$843kNew position
- May 8 – 11Scott SchlackmanDirector · bought 5,000 at avg $12.59$63k20% of stake
- Mar 20Daniel R ChardChairman & CEO · bought 17,678 at $10.11$179k5.2% of stake
- Jun 13, 2025Daniel R ChardChairman & CEO · bought 381 at $13.13$5k0.1% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Related stocks: Miscellaneous Food Preparations & Kindred Products
Spot a number that looks wrong? Check it in MED's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MED
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.